AKT1 and goblet cell carcinoma: This stresses the value of FoxO as a potential biomarker when considering PI3K/AKT inhibitor-based treatment, especially in tumors that have been detected to possess both PI3K/AKT and FoxO enrichment, like appendiceal goblet cell adenocarcinoma subtype [51].